CLINICAL TRIALS PROFILE FOR CHLORPROTHIXENE

All Clinical Trials for chlorprothixene

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01309178 ↗	Anti-inflammatory Pulmonal Therapy of Cystic Fibrosis (CF) Patients With Amitriptyline and Placebo	Unknown status	Universität Duisburg-Essen	Phase 2	2009-05-01	Cystic fibrosis patients suffer from a chronic destruction of the lung, frequent and finally chronic pneumonia and a reduced life expectancy. Unfortunately, no curative treatment for cystic fibrosis is available, neither are treatments established that prevent the disease. Our data identify ceramide as a potential novel target to treat cystic fibrosis. Two smaller trials support the notion that inhibition of the acid sphingomyelinase by amitriptyline improves the lung function of CF-patients even at a dose that is low enough to avoid adverse effects. In the present proposal the investigators, therefore, aim to test in a larger cystic fibrosis patient population whether an inhibition of ceramide release in the lung caused by the lack of functional CFTR improves the lung function of cystic fibrosis patients. Inhibition of ceramide-release in the lung will be achieved by treatment with amitriptyline, which is used as an anti-depressant drug for almost 50 years. Although it is not absolutely specific, it seems to be relatively specific for the degradation of acid sphingomyelinase (typically 60-80% of cellular acid sphingomyelinase are degraded), which releases ceramide from sphingomyelin. If the data confirm the beneficial effect of amitriptyline already observed in our preliminary studies, the present clinical study may establish a novel treatment to improve clinical symptoms of cystic fibrosis and, moreover, to prevent or at least delay the onset of cystic fibrosis. Hypothesis - Amitriptyline reduces ceramide concentrations in respiratory epithelial cells (measured in nasal epithelial cells obtained by brushing nasal mucosa). - Amitriptyline treatment reduces cell death in bronchi and deposition of DNA on the respiratory epithelium, which permits elimination of P. aeruginosa from the lung (measured as P. aeruginosa counts in tracheal fluid). - Amitriptyline treatment results in normalization of the function of leukocytes (number determined in serum and tracheal fluid) - Amitriptyline reduces systemic and local inflammation (measured as cytokines in plasma and tracheal fluid). Based on these effects amitriptyline increases the lung function of cystic fibrosis patients (measured by FEV1).
NCT01309178 ↗	Anti-inflammatory Pulmonal Therapy of Cystic Fibrosis (CF) Patients With Amitriptyline and Placebo	Unknown status	University of Ulm	Phase 2	2009-05-01	Cystic fibrosis patients suffer from a chronic destruction of the lung, frequent and finally chronic pneumonia and a reduced life expectancy. Unfortunately, no curative treatment for cystic fibrosis is available, neither are treatments established that prevent the disease. Our data identify ceramide as a potential novel target to treat cystic fibrosis. Two smaller trials support the notion that inhibition of the acid sphingomyelinase by amitriptyline improves the lung function of CF-patients even at a dose that is low enough to avoid adverse effects. In the present proposal the investigators, therefore, aim to test in a larger cystic fibrosis patient population whether an inhibition of ceramide release in the lung caused by the lack of functional CFTR improves the lung function of cystic fibrosis patients. Inhibition of ceramide-release in the lung will be achieved by treatment with amitriptyline, which is used as an anti-depressant drug for almost 50 years. Although it is not absolutely specific, it seems to be relatively specific for the degradation of acid sphingomyelinase (typically 60-80% of cellular acid sphingomyelinase are degraded), which releases ceramide from sphingomyelin. If the data confirm the beneficial effect of amitriptyline already observed in our preliminary studies, the present clinical study may establish a novel treatment to improve clinical symptoms of cystic fibrosis and, moreover, to prevent or at least delay the onset of cystic fibrosis. Hypothesis - Amitriptyline reduces ceramide concentrations in respiratory epithelial cells (measured in nasal epithelial cells obtained by brushing nasal mucosa). - Amitriptyline treatment reduces cell death in bronchi and deposition of DNA on the respiratory epithelium, which permits elimination of P. aeruginosa from the lung (measured as P. aeruginosa counts in tracheal fluid). - Amitriptyline treatment results in normalization of the function of leukocytes (number determined in serum and tracheal fluid) - Amitriptyline reduces systemic and local inflammation (measured as cytokines in plasma and tracheal fluid). Based on these effects amitriptyline increases the lung function of cystic fibrosis patients (measured by FEV1).
NCT01309178 ↗	Anti-inflammatory Pulmonal Therapy of Cystic Fibrosis (CF) Patients With Amitriptyline and Placebo	Unknown status	University Children's Hospital Tuebingen	Phase 2	2009-05-01	Cystic fibrosis patients suffer from a chronic destruction of the lung, frequent and finally chronic pneumonia and a reduced life expectancy. Unfortunately, no curative treatment for cystic fibrosis is available, neither are treatments established that prevent the disease. Our data identify ceramide as a potential novel target to treat cystic fibrosis. Two smaller trials support the notion that inhibition of the acid sphingomyelinase by amitriptyline improves the lung function of CF-patients even at a dose that is low enough to avoid adverse effects. In the present proposal the investigators, therefore, aim to test in a larger cystic fibrosis patient population whether an inhibition of ceramide release in the lung caused by the lack of functional CFTR improves the lung function of cystic fibrosis patients. Inhibition of ceramide-release in the lung will be achieved by treatment with amitriptyline, which is used as an anti-depressant drug for almost 50 years. Although it is not absolutely specific, it seems to be relatively specific for the degradation of acid sphingomyelinase (typically 60-80% of cellular acid sphingomyelinase are degraded), which releases ceramide from sphingomyelin. If the data confirm the beneficial effect of amitriptyline already observed in our preliminary studies, the present clinical study may establish a novel treatment to improve clinical symptoms of cystic fibrosis and, moreover, to prevent or at least delay the onset of cystic fibrosis. Hypothesis - Amitriptyline reduces ceramide concentrations in respiratory epithelial cells (measured in nasal epithelial cells obtained by brushing nasal mucosa). - Amitriptyline treatment reduces cell death in bronchi and deposition of DNA on the respiratory epithelium, which permits elimination of P. aeruginosa from the lung (measured as P. aeruginosa counts in tracheal fluid). - Amitriptyline treatment results in normalization of the function of leukocytes (number determined in serum and tracheal fluid) - Amitriptyline reduces systemic and local inflammation (measured as cytokines in plasma and tracheal fluid). Based on these effects amitriptyline increases the lung function of cystic fibrosis patients (measured by FEV1).
NCT01309178 ↗	Anti-inflammatory Pulmonal Therapy of Cystic Fibrosis (CF) Patients With Amitriptyline and Placebo	Unknown status	University Children’s Hospital Tuebingen	Phase 2	2009-05-01	Cystic fibrosis patients suffer from a chronic destruction of the lung, frequent and finally chronic pneumonia and a reduced life expectancy. Unfortunately, no curative treatment for cystic fibrosis is available, neither are treatments established that prevent the disease. Our data identify ceramide as a potential novel target to treat cystic fibrosis. Two smaller trials support the notion that inhibition of the acid sphingomyelinase by amitriptyline improves the lung function of CF-patients even at a dose that is low enough to avoid adverse effects. In the present proposal the investigators, therefore, aim to test in a larger cystic fibrosis patient population whether an inhibition of ceramide release in the lung caused by the lack of functional CFTR improves the lung function of cystic fibrosis patients. Inhibition of ceramide-release in the lung will be achieved by treatment with amitriptyline, which is used as an anti-depressant drug for almost 50 years. Although it is not absolutely specific, it seems to be relatively specific for the degradation of acid sphingomyelinase (typically 60-80% of cellular acid sphingomyelinase are degraded), which releases ceramide from sphingomyelin. If the data confirm the beneficial effect of amitriptyline already observed in our preliminary studies, the present clinical study may establish a novel treatment to improve clinical symptoms of cystic fibrosis and, moreover, to prevent or at least delay the onset of cystic fibrosis. Hypothesis - Amitriptyline reduces ceramide concentrations in respiratory epithelial cells (measured in nasal epithelial cells obtained by brushing nasal mucosa). - Amitriptyline treatment reduces cell death in bronchi and deposition of DNA on the respiratory epithelium, which permits elimination of P. aeruginosa from the lung (measured as P. aeruginosa counts in tracheal fluid). - Amitriptyline treatment results in normalization of the function of leukocytes (number determined in serum and tracheal fluid) - Amitriptyline reduces systemic and local inflammation (measured as cytokines in plasma and tracheal fluid). Based on these effects amitriptyline increases the lung function of cystic fibrosis patients (measured by FEV1).

Clinical Trial Conditions for chlorprothixene

Condition Name

Condition Name for chlorprothixene
Intervention	Trials
Schizophrenia	2
Psychosomatic Disorders	1
Psychotic Disorders	1
Schizoaffective Disorder	1

Condition MeSH

Condition MeSH for chlorprothixene
Intervention	Trials
Disease	2
Schizophrenia	2
Mental Disorders	1
Cystic Fibrosis	1

Clinical Trial Locations for chlorprothixene

Trials by Country

Trials by Country for chlorprothixene
Location	Trials
Germany	2
Canada	1

Clinical Trial Progress for chlorprothixene

Clinical Trial Phase

Clinical Trial Phase for chlorprothixene
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for chlorprothixene
Clinical Trial Phase	Trials
Completed	1
Terminated	1
Unknown status	1

Clinical Trial Sponsors for chlorprothixene

Sponsor Name

Sponsor Name for chlorprothixene
Sponsor	Trials
Universität Duisburg-Essen	1
University of Ulm	1
University Children's Hospital Tuebingen	1

Sponsor Type

Sponsor Type for chlorprothixene
Sponsor	Trials
Other	8

Last updated: May 2, 2026

Clinical Trials Update, Market Analysis, and Projection for Chlorprothixene

What is chlorprothixene’s current clinical-development footprint?

Chlorprothixene is an older first-generation antipsychotic (thioxanthene class). It has long-standing marketing history in multiple jurisdictions, but active late-stage development pipelines are not evident from public trial registries in the way seen for modern monoclonal antibodies or oncology drugs. Public clinical activity is dominated by historical use, label maintenance, and small pharmacology or observational studies rather than phase 3 registration trials.

Clinical-trial visibility (public record pattern)

• No consistently evidenced, ongoing phase 3 (registration) program for a new chlorprothixene indication was identifiable in public-facing clinical trial registries at the level typically required for label expansion.
• Development activity, when present, is usually smaller-scale (e.g., pharmacokinetics, comparative tolerability, or observational cohorts) rather than new pivotal efficacy packages.

Implication for investors and R&D

• The near-term value case is not driven by “pipeline maturation” into phase 3 readouts.
• The practical path is label maintenance, life-cycle management (dose form, country-specific approvals), and competitive positioning where chlorprothixene remains a clinically accepted option.

What are chlorprothixene’s market characteristics and demand drivers?

Chlorprothixene competes in a crowded global antipsychotic landscape dominated by:

• Second-generation antipsychotics (SAs) with broad guideline inclusion and strong branded/generic availability in most high-income markets
• First-generation antipsychotics with persistent use where budgets are constrained or specific clinical profiles support older agents

Primary usage context

• Schizophrenia-spectrum disorders and other psychotic states in settings where older antipsychotics remain in formulary.
• Short- to medium-term management in some regions, with regimen switching influenced by adverse effect profiles, patient history, and local prescribing norms.

Market structure

• Generic-led economics: Older molecules typically price under branded compounds once multiple generic entrants establish supply.
• Institutional formularies: Demand is controlled by hospital and national procurement decisions more than consumer-level brand pull.

Commercial headwinds

• Ongoing clinician preference for SAs due to perceived side-effect profile advantages in routine practice.
• Safety and tolerability comparisons: first-generation agents face persistent scrutiny for extrapyramidal symptoms and related adverse events.

Where does chlorprothixene still fit competitively?

Chlorprothixene’s competitive window is typically driven by:

• Local guideline alignment where first-generation agents remain listed options
• Availability and procurement pricing where generics are widely accessible
• Formulary inertia: long-standing prescribing patterns can sustain demand even as newer agents expand

Competitive benchmark (positioning reality)

• Against SAs: chlorprothixene has lower marketing leverage and must win on cost, access, and patient-fit within local prescribing frameworks.
• Against other first-generation agents: value is more about availability in specific geographies and clinician comfort.

How to project chlorprothixene’s market trajectory (base, downside, upside)?

Because chlorprothixene is an established generic/heritage antipsychotic in most markets, projections should be modeled like a mature commodity-with-formulary influence, not like a growth-stage specialty pipeline.

Projection framework (practical for equity and pharma business models) Use three drivers:

1. Patient volume stability (prevalence-driven, but influenced by diagnosis patterns and switching)
2. Share of formulary (procurement and guideline-driven)
3. Price erosion (generic competition, tender dynamics)

Base-case assumptions (typical for mature generics)

• Volume: stable to low-growth in regions where formularies maintain first-generation options
• Price: continued erosion (annual mid-single-digit to high-single-digit declines in many mature generic segments, varying by tender intensity and regional policy)
• Net sales: low to mid single-digit growth only if volume gains or new market access offsets price erosion; otherwise flat to declining.

Downside case

• Accelerated formulary exclusion where SAs dominate procurement
• Faster price erosion from additional generic supply
• Net sales contraction.

Upside case

• New or expanded regional access, or renewed inclusion in local treatment algorithms
• Tender outcomes that preserve relative pricing
• Net sales modest growth.

Market outlook table (directional projection)

The projection below is directional because chlorprothixene’s sales are typically not reported at a global brand level in a standardized way for public datasets. Use it for scenario planning rather than exact forecast-grade revenue numbers.

Scenario	Volume trend	Price trend	Net sales trajectory	Business implication
Base	Stable to slight growth in select markets	Ongoing erosion	Flat to low growth	Focus on access and formulary retention
Downside	Decline as formularies switch to SAs	Faster erosion	Low to moderate decline	Defense strategy: contracts, supply continuity
Upside	Growth from access gains	Slower erosion	Moderate growth	Invest in tenders, local evidence, lifecycle

What does a clinical trials update mean for product strategy now?

A “clinical trials update” for chlorprothixene is usually an evidence maintenance exercise. Since major label expansions are not clearly tied to ongoing late-stage trials, the operational strategy is:

• Preserve regulatory standing and product quality across jurisdictions
• Target submissions that support specific local prescribing needs (dose forms, safety updates, pharmacovigilance)
• Use real-world evidence where required to sustain inclusion

Key milestones to monitor (execution watchlist)

Without an identifiable phase 3 registration push, monitoring becomes governance and market-execution focused:

• Regulatory label maintenance: changes to warnings, safety sections, and local indication language
• Formulary events: national tender cycles and hospital formulary changes that shift first-generation vs second-generation mix
• Generic supply dynamics: entry of new manufacturers that accelerates price erosion
• Safety signal monitoring: pharmacovigilance trends that can change clinician comfort and procurement preferences

What is the investment thesis shape for chlorprothixene?

The chlorprothixene business thesis is mostly about:

• Regional access (where it stays on formulary)
• Cost of goods and supply reliability (scale advantage)
• Contracting and tender outcomes (price stabilization or erosion speed)
• Regulatory durability (no disruptive safety or label restrictions)

This is a mature product profile, where the dominant levers are commercial execution and compliance rather than clinical differentiation.

---

Key Takeaways

• Chlorprothixene’s clinical activity is not characterized by a visible phase 3 registration pipeline; evidence is more consistent with maintenance-level studies and real-world use.
• The market behaves like a mature antipsychotic segment: price erosion and formulary control dominate, with second-generation antipsychotics exerting structural pressure.
• Projection should be scenario-based using three levers: patient volume stability, formulary share, and price erosion.
• Near-term value is driven by tender outcomes, supply continuity, and regulatory durability rather than new pivotal efficacy readouts.

---

FAQs

1) Does chlorprothixene have an active phase 3 trial program driving new approvals?

Publicly visible late-stage registration activity is not evident in the way that would indicate a major new label expansion driven by phase 3 results.

2) What determines chlorprothixene’s sales in most markets?

Formulary inclusion, procurement/tender outcomes, and pricing versus alternative antipsychotics are the primary determinants.

3) How does second-generation competition affect chlorprothixene demand?

It typically reduces share as guidelines and procurement shift toward second-generation antipsychotics, especially where safety comparisons influence formulary decisions.

4) What is the main risk in forecasting chlorprothixene market trajectory?

Price erosion speed and abrupt formulary changes during procurement cycles, which can overwhelm any modest volume stability.

5) What is the most effective near-term strategy for a chlorprothixene business?

Defend and expand formulary access through contracting, ensure reliable supply, and maintain regulatory and pharmacovigilance readiness.

---

References

[1] ClinicalTrials.gov. Search results for chlorprothixene (accessed 2026-05-03).
[2] EU Clinical Trials Register. Search results for chlorprothixene (accessed 2026-05-03).
[3] WHO Collaborating Centre for Drug Statistics Methodology (ATC/DDD) and related substance records for chlorprothixene (accessed 2026-05-03).
[4] PubMed. Chlorprothixene-related publications and study records (accessed 2026-05-03).